Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1

BS Gosis, S Wada, C Thorsheim, K Li, S Jung… - Science, 2022 - science.org
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain
without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) …
被引用次数：76 相关文章

Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1

BS Gosis, S Wada, C Thorsheim, K Li, S Jung… - Science, 2022 - pure.psu.edu
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain
without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) …

Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1.

BS Gosis, S Wada, C Thorsheim, K Li… - Science (New York …, 2022 - escholarship.org
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain
without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) …

Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1

BS Gosis, S Wada, C Thorsheim, K Li, S Jung… - paper.sciencenet.cn
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain
without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) …
[HTML] nih.gov

[HTML][HTML] Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1

BS Gosis, S Wada, C Thorsheim, K Li… - Science (New York …, 2022 - ncbi.nlm.nih.gov
RESULTS: Hepatocyte-specific genetic deletion of Flcn in adult mice selectively inhibited
mTORC1-mediated cytoplasmic sequestration of TFE3, with little effect on other mTORC1 …

Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1.

BS Gosis, S Wada, C Thorsheim, K Li, S Jung… - Science (New York …, 2022 - europepmc.org
A comment on this article appears in" Targeting folliculin to selectively inhibit mTORC1: a
promising strategy for treating nonalcoholic fatty liver disease." Signal Transduct Target …

Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1

BS Gosis, S Wada, C Thorsheim, K Li… - … (New York, NY), 2022 - pubmed.ncbi.nlm.nih.gov
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain
without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) …

Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1.

BS Gosis, S Wada, C Thorsheim, K Li, S Jung… - Science (New York …, 2022 - europepmc.org
INTRODUCTION: As many as 100 million people in the US have nonalcoholic fatty liver
disease (NAFLD), characterized by increased liver lipid accumulation, which often leads to …